Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide

Abstract

Glioblastoma is the most common and aggressive brain tumor and it is characterized by a high mortality rate. Temozolomide (TMZ) is an effective chemotherapy drug for glioblastoma, but the resistance to TMZ has come to represent a major clinical problem, and its underlying mechanism has yet to be elucidated. In the present study, the role of exosomal connexin 43 (Cx43) in the resistance of glioma cells to TMZ and cell migration was investigated. First, higher expression levels of Cx43 were detected in TMZ-resistant U251 (U251r) cells compared with those in TMZ-sensitive (U251s) cells. Exosomes from U251s or U251r cells (sExo and rExo, respectively) were isolated. It was found that the expression of Cx43 in rExo was notably higher compared with that in sExo, whereas treatment with rExo increased the expression of Cx43 in U251s cells. Additionally, exosomes stained with dioctadecyloxacarbocyanine (Dio) were used to visualized exosome uptake by glioma cells. It was observed that the uptake of Dio-stained rExo in U251s cells was more prominent compared with that of Dio-stained sExo, while ^37,43Gap27, a gap junction mimetic peptide directed against Cx43, alleviated the rExo uptake by cells. Moreover, rExo increased the IC₅₀ of U251s to TMZ, colony formation and Bcl-2 expression, but decreased Bax and cleaved caspase-3 expression in U251s cells. ^37,43Gap27 efficiently inhibited these effects of rExo on U251s cells. Finally, the results of the wound healing and Transwell assays revealed that rExo significantly enhanced the migration of U251s cells, whereas ^37,43Gap27 significantly attenuated rExo-induced cell migration. Taken together, these results indicate the crucial role of exosomal Cx43 in chemotherapy resistance and migration of glioma cells, and suggest that Cx43 may hold promise as a therapeutic target for glioblastoma in the future.

Introduction

Glioma is a type of aggressive tumor originating from the neuroectoderm and accounts for 45–50% of all intracranial tumors (1). According to the 2007 WHO central nervous system tumor grading system, malignant gliomas, including glioblastoma, anaplastic astrocytoma, anaplastic oligodendrocyte tumor and anaplastic oligodendroglioma (WHO grade III–IV) account for more than half of all gliomas (2). Malignant glioma is a solid tumor composed of rapidly proliferating non-glial cells, and is characterized by intra- and intertumor heterogeneity, resistance to chemotherapy and poor prognosis (3). Due to its characteristic malignant invasive growth, the therapeutic approach has evolved from a single surgical approach to a combination of surgical approaches with radiotherapy and chemotherapy. However, the median survival of patients with glioblastoma only increased from 12.1 with radiotherapy alone to 14.6 months with radiotherapy plus temozolomide, and the prognosis of patients did not significantly improve (4).

Temozolomide (TMZ) is an oral DNA alkylating agent, which inactivates O6-methylguanine-DNA alkyl transferase (5), forms a notch for substrate DNA, and causes DNA double strand breaks and cell cycle arrest in the G2/M phase, eventually leading to cell apoptosis (6). TMZ readily crosses the blood-brain barrier; thus, it is one of the most effective chemotherapeutic drugs for glioma (7). However, TMZ is only ~45% effective against malignant glioma (8), and a significant proportion of gliomas develop resistance to TMZ during treatment. The emergence of chemotherapy resistance and subsequent disease recurrence have become an urgent clinical problem in glioma (9). Most studies on TMZ resistance in gliomas are focused on drug efflux mediated by ABC transporters, repair of damaged DNA, changes in apoptotic pathways, cell cycle and cell metabolism (10,11). All these mechanisms are closely intertwined, and may be implicated in the development of chemotherapy resistance (12). However, other underlying mechanisms may also be involved in the development of resistance. Thus, the exact molecular mechanisms underlying resistance of glioma to chemotherapy remain to be further elucidated.

Exosomes are lipid bilayer vesicles with a diameter of 30–150 nm that are actively produced by almost all cells (13,14). Exosomes are developed from early endosomes, and usually express specific surface markers, including CD9, CD63, TSG101, Alix and Flotillin-1 (15). Exosomes contain non-coding RNAs, lipids and up to 7,000 proteins, and they mediate cell-cell communication by delivering these substances to surrounding cells (16). It was previously demonstrated that exosomes play an important role in the migration, invasion and chemotherapy resistance of cancer cells (17). Exosomes may alter the tumor microenvironment and promote drug resistance through transferring various drug resistance-related factors between drug-resistant and drug-sensitive cells, and between drug-resistant cells and tumor stromal cells (18–20). Most studies have focused on the role of exosomal contents, but a few also reported that exosomal membrane components may affect the recognition and uptake of exosomes by recipient cells (21). Exosomes interact with recipient cells through receptor-ligand interaction, endocytosis and membrane fusion (22). Phagocytic cells, such as macrophages, are more likely to endocytose exosomes (23). Non-phagocytic cells, such as T-lymphocyte subsets, express receptors for binding with the ligands on exosomes, thereby mediating membrane fusion and delivering exosomal contents to recipient cells (24). In the latter case, exosomal membrane components play an important role in the uptake of exosomes by recipient cells. Recently, it was reported that connexins (Cxs) may also be assembled into a hemi-channel in the membrane of exosomes secreted by cells (25). Therefore, it is crucial to investigate whether exosomal Cxs are involved in the interaction between exosomes and recipient cells.

Cxs are transmembrane proteins composed of two extracellular rings, an intracellular ring, an amino and a carboxyl tail domain (26). More than 20 Cxs have been identified in humans and mice (27). Cxs can oligomerize on the cell membrane to form gap junction hemi-channels, which are docked and assembled into gap junction channels to mediate gap junction intercellular communication. Cx43 is one of the most common Cxs, and is involved in tumor invasion, progression, and the resistance of glioma cells to TMZ (28–30). It has also been reported that the expression level of Cx43 in gliomas is higher compared with that in the adjacent tissues (31), which suggests the role of Cx43 in gliomagenesis. Moreover, upregulated expression of Cx43 through epidermal growth factor receptor-activated c-Jun N-terminal kinase/extracellular signal-regulated kinase 1/2/activator protein-1 signaling axis has been found in TMZ-resistant glioblastoma cell lines (32).

The present study was undertaken to investigate the role of exosomal Cx43 in the resistance of glioma cells to TMZ and cell migration. The expression of Cx43 was examined in TMZ-resistant and TMZ-sensitive U251 cells (U251r and U251s, respectively) as well as in their exosomes (sExo and rExo, respectively). The effects of rExo on the IC₅₀ of U251s cells to TMZ, colony formation ability, Bcl-2 expression, cell migration and Bax expression were also examined. Furthermore, it was investigated whether pretreatment with the gap junction mimetic peptide ^37,43Gap27 would be able to inhibit the uptake of rExo by U251s cells, and alleviate rExo-induced TMZ resistance, colony formation and migration of U251s cells. The aim was to elucidate the role of exosomal Cx43 in chemotherapy resistance and migration of glioma cells, and determine whether it may serve as a therapeutic target for glioblastoma in the future.

Materials and methods

Chemicals and reagents

Fetal bovine serum (FBS) was purchased from EVERY GREEN (Biotech Co.). Dulbecco's modified Eagle's medium (DMEM), DMSO, PMSF, crystal violet, 4% paraformaldehyde, anti-fluorescence attenuation sealant, trypsin and penicillin-streptomycin solution (P/S) were purchased from Beijing Solarbio Science & Technology Co., Ltd. Tween-20 and TEMED were purchased from Sigma-Aldrich; Merck KGaA. TMZ was obtained from MedChemExpress. ^37,34Gap27 was purchased from Eurogentec. PrimeScript™ RT reagent Kit (cat. no. RR037A) with gDNA Eraser and QuantiNova™ SYBR^®-Green PCR Kit (cat. no. RR420A) were obtained from Takara Bio, Inc.

Cell culture

U251s and U251r cells were purchased from the American Type Culture Collection. The human U251s and U251r cell lines were grown in DMEM supplemented with 10% FBS and 100 µg/ml P/S in a humidified incubator at 37°C with an atmosphere containing 5% CO₂.

Reverse transcription-quantitative PCR (RT-PCR)

Total RNA was isolated from cells using Eastep^® Super (Promega Corporation). Reverse transcription was performed using PrimeScript™ RT reagent Kit (Takara Bio, Inc.) at 37°C for 15 min, 85°C for 5 sec and then held at 4°C. qPCR was performed using TB Green^® Premix Ex Tap™ (Takara Bio, Inc.) on CFX Connect™ Real-time System (Bio-Rad Laboratories, Inc.) at 95°C for 30 sec, for 39 thermal cycles (95°C for 5 sec and 60°C for 30 sec), with GAPDH serving as the internal control. The sequences of the primers used for RT-PCR are presented in Table I.

Table I.

Primer sequences.

	Sequences (5′→3′)
Gene names	Forward	Reverse
Connexin 43	CAAAATCGAATGGGGAGGC	GCTGGTCCACAATGGCTAGT
GAPDH	GTCAAGGCTGAGAACGGGAA	AAATGAGCCCCAGCCTTCTC

Western blotting

Cells were harvested and lysed by RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) according to the manufacturer's instructions. Protein concentrations were determined with BCA Protein Assay Kit (Applygen Technologies, Inc.). Protein samples (18 µg) were separated by 10% SDS-PAGE (Bio-Rad Laboratories, Inc.) and transferred to PVDF membranes by Trans-Blot SD type membrane transfer system (Bio-Rad Laboratories, Inc.). After blocking with 5% skimmed milk for 1 h at room temperature, proteins on the PVDF membranes were immunoblotted for 2 h at room temperature using primary antibodies for Cx43 (cat. no. ab79010; Abcam, 1:1,000), Bax (cat. no. 2772; Cell Signaling Technology, Inc., 1:1,000), Bcl-2 (cat. no. YT0407; ImmunoWay, 1:1,000), cleaved caspase-3 (cat. no. 9664; Cell Signaling Technology, Inc., 1:1,000), TSG101 and CD63 (cat. no. DF8427 and cat. no. AF5117; Affinity Biosciences, 1:1,000) and GADPH (cat. no. 70004; Affinity Biosciences, 1:2,000). After washing for 3 times, the membranes were further incubated with HRP-conjugated goat anti-mouse (cat. no. GAM007; MultiSciences Biotech Co., Ltd., 1:2,000) or goat anti-rabbit (cat. no. BA1060; Boster Biological Technology Co., Ltd., 1:2,000) antibodies at room temperature for 1 h. The chemiluminescence signals were detected with an enhanced chemiluminescence assay kit (Beijing Kangwei Century Biotechnology Co., Ltd.). Densitometric analysis was conducted with the Gel Imaging System (Analytik Jena US LLC).

Isolation and identification of exosomes

Exosomes were isolated by differential velocity centrifugation. In brief, culture medium was initially subjected to centrifugation at 300 × g for 10 min, 2,000 × g for 10 min and 10,000 × g for 30 min at 4°C. The supernatant was further subjected to centrifugation at 100,000 × g for 70 min at 4°C, and pellets rich in exosomes were resuspended in 1X PBS. To identify the isolated exosomes, the particle size of exosomes was initially determined by Zetasizer Nano ZS 90 particle size analyzer (Malvern Panalytical), and the morphology of the exosomes was observed under a transmission electron microscope (Leica Microsystems GmbH; magnification, ×40,000). As described previously (33), 10 µl of sample was added to a 2-mm copper mesh grid and the excess PBS was removed with a filter paper. Then, 10 µl of phosphotungstate (20 g/l) was added to the copper net for negative staining for 2 min and grilled under an incandescent lamp for 5 min. The isolated samples were subjected to 10% SDS-PAGE, and western blotting was used to detect the marker proteins TSG101 and CD63 on exosomes.

Exosome uptake experiment

To label exosomes, 10 µM of dioctadecyloxacarbocyanine (Dio) membrane dye was added to the exosomal suspension in a 1:1 ratio and incubated at 37°C in the dark for 30 min, followed by washing with PBS and centrifugation at 100,000 × g for 70 min for 3 times to remove the free Dio dye. The Dio-labeled exosomes were resuspended with sterile 1X PBS. The exosome concentration was detected by the BCA Protein Assay. Three concentrations of 25, 50 and 100 µg/ml were used in the cell treatment experiments. The results revealed that the effect of rExo at 25 µg/ml was weak, while rExo at 50 and 100 µg/ml markedly affected Cx43 expression in U251 cells. Therefore, the concentration of exosomes at 50 µg/ml was considered sufficient and was used for the following cell treatment experiments. In the control groups, the same volume of PBS was added to the cells. To detect uptake of exosomes, U251s cells were incubated with 50 µg/ml of Dio-labeled rExo or sExo for 30 min at 37°C in the dark. Then, the cells were washed twice with PBS, and fixed with 4% paraformaldehyde for 10 min on ice. The nuclei of U251s cells were counterstained with 500 µl of Hoechst 33342 (10 µg/ml) for 5 min at room temperature in the dark. Finally, the cells were washed three times with PBS. The uptake of Dio-labeled exosomes by cells was observed under an inverted fluorescence microscope (Leica Microsystems GmbH; magnification, ×400).

Cell viability detection

The Cell Counting Kit-8 (CCK-8; Vazyme Biotech Co., Ltd.) assay was performed to evaluate the viability of U251s and U251r cells according to the manufacturer's instructions. Briefly, ~4×10³ cells were seeded on 96-well plates and cultured in full growth medium. After incubation with TMZ at 0, 100, 200, 400, 600, 800, 1,000 and 1,200 µM for 72 h, 10 µl of CCK-8 was added to each well, and cells were further incubated with CCK-8 for ~2 h. The absorbance at 450 nm was measured spectrophotometrically using a microplate reader (Bio-Rad Laboratories, Inc.). Control and blank wells were also detected. All assays were performed at least three times.

Colony formation assay

U251s Cells were incubated with 1X PBS, 50 µg/ml of sExo or rExo and rExo + 200 µM ^37,43Gap27 for 48 h. After incubation, cells were harvested and resuspended to a density of 6×10³/ml. a total of 50 µl cell suspension was inoculated in a 6-well plate, and was further cultured for 10 days. Then, the cells were washed with 1X PBS and fixed in 4% paraformaldehyde for 15 min on ice. A total of 2 ml of crystal violet solution (0.1%) was added to each well and the cells were stained for 30 min at room temperature. After washing 3 times with 1X PBS, the number of colonies with >50 cells was counted.

Wound healing and Transwell assays

The wound healing and Transwell assays were performed as previously described (34). For the wound healing assay, 3×10⁵ U251s cells were seeded on 35-mm culture dishes. When the cell confluence reached ~90%, a scratch was made in monolayer of cells with a 200-µl pipette tip. After removing unattached cells, U251 cells were incubated with 1X PBS, 50 µg/ml of sExo or rExo and rExo + 200 µM ^37,43Gap27 for 48 h. At 0, 24 and 48 h of incubation with the aforementioned reagents, the cells were photographed for evaluation of wound closure under an inverted microscope (DMi8; Leica Microsystems GmbH; magnification, ×100). ImageJ software (1.52v; National Institutes of Health) was used to calculate the area of migration. Transwell chambers (Corning, Inc.) were used for Transwell assay. Briefly, 3×10⁶ U251s cells incubated with 1X PBS, 50 µg/ml of sExo or rExo and rExo + 200 µM ^37,43Gap27 for 48 h were inoculated in the upper chamber with 200 µl serum-free medium. The upper chamber was then incubated in a 24-well plate chamber with complete medium containing 10% FBS for 24 h. After removing the cells on the top surface of the upper chamber, the migrated cells on lower surface of the chamber were fixed in 4% paraformaldehyde solution for 10 min at room temperature, then stained in 0.1% crystal violet solution for 30 min at room temperature. The migrated cells were photographed under an inverted microscope (DMi8; Leica Microsystems GmbH) and counted in four random fields at a magnification of ×200.

Statistical analysis

The data in the present study were analyzed with GraphPad Prism v.5 (GraphPad Software, Inc.) and are presented as the mean ± SD. The statistical significance of the differences among multiple groups was analyzed by one-way ANOVA parametric testing followed by Tukey's multiple comparisons test. In the case of comparison between two groups, unpaired two-tailed Student's t-test was performed. P<0.05 was considered to indicate statistically significant differences.

Results

Cx43 expression is upregulated in TMZ-resistant U251r cells

To investigate the role of Cx43 in the chemotherapy resistance of glioblastoma cells, the mRNA and protein levels of Cx43 were measured in U251r and U251s cells using RT-PCR and western blotting assays, respectively. As shown in Fig. 1A and B, the mRNA level of Cx43 in U251r cells was significantly higher compared with that in U251s cells. Similarly, the results of western blotting demonstrated that the Cx43 protein level was also significantly higher in U251r cells compared with that in U251s cells (Fig. 1C and D; P<0.01). These results are consistent with those of previous studies (31,32), and suggest that Cx43 may be involved in the resistance of glioblastoma cells to TMZ.

Figure 1.

Cx43 mRNA and protein levels in U251s and U251r cells. (A and B) Cx43 mRNA levels in U251s and U251r cells were detected by reverse transcription-quantitative PCR. The transcription of GAPDH was used as endogenous control. (C and D) Cx43 protein expression level in U251s and U251r cells. GAPDH was used as endogenous control. (B and D) Cx43 mRNA and protein levels in U251s and U251r cells were quantitatively analyzed from data of at least three independent experiments. **P<0.01. Cx43, connexin 43; U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; RFU, relative fluorescence units.

Isolation and identification of exosomes from U251s and U251r cells

First, exosomes were isolated from U251s and U251r cells by differential velocity centrifugation, as previously described (35). After isolation, the morphology of the vesicles was observed under a transmission electron microscope (Fig. 2A). It has been reported that exosomes are lipid bilayer vesicles with a diameter of 30–150 nm. The samples isolated from U251s and U251r cells were subjected to Zetasizer Nano ZS 90 particle size analyzer. As shown in Fig. 2B, the size distribution of the vesicles was concentrated in the range of 40–120 nm. Thus, the morphology and particle size distribution of vesicles isolated from cells were found to be consistent with the characteristics of exosomes. Furthermore, western blotting was used to detect the expression of exosomal markers, including CD63 and TSG101, in isolated samples. The results revealed that a strong signal of CD63 and TSG101 was detected in samples isolated from U251s and U251r cells, while the signal was notably weaker in whole-cell lysate from U251s cells (Fig. 2C-E). These results indicate that the exosomes (sExo and rExo) were successfully isolated from U251s and U251r cells, respectively.

Figure 2.

Isolation and identification of exosomes from U251s and U251r cells. (A) Exosomes were isolated from U251s or U251r cells by differential velocity centrifugation, and representative images of sExo and rExo were captured under a transmission electron microscope. Scale bar, 200 nm. (B) sExo and rExo diameters were measured using the Zetasizer Nano ZS90 particle size analyzer. The size distribution of the vesicles was concentrated in the range of 40–120 nm. (C) Western blotting was used to examine the expression of exosomal markers CD63 and TSG101 in U251s cells, sExo and rExo; GAPDH was used as an endogenous reference. (D and E) Quantitative analysis of the protein expression level of CD63 and TSG101. **P<0.01, ***P<0.001. U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells.

rExo upregulates Cx43 expression in U251s cells and facilitates exosome uptake via Cx43

It has been reported that Cxs can be assembled into a hemi-channel in the exosomal membrane (24). To explore the role of Cx43 in TMZ resistance, the expression of Cx43 in sExo and rExo was detected by western blotting. As shown in Fig. 3A and C, the expression of Cx43 in rExo was significantly higher compared with that in sExo (P<0.005). In addition, the effect of sExo and rExo on Cx43 expression in glioma cells was examined. U251s cells were incubated with 50 µg/ml sExo, rExo and PBS for 48 h. Of note, the expression of Cx43 in U251s cells incubated with rExo was significantly increased, while there was no significant change in the expression of Cx43 in U251s cells treated with PBS or sExo (Fig. 3B and D). Next, the role of Cx43 in exosome uptake by glioma cells was further explored. U251s cells were incubated with Dio-sExo, Dio-rExo or Dio-rExo + ^37,43Gap27. As shown in Fig. 3E, the uptake of sExo and rExo by U251s cells was observed. Consistent with exosomal Cx43 expression level, the fluorescence intensity of Dio-rExo in U251s cells was found to be stronger compared with that of Dio-sExo groups. Moreover, the gap junction mimetic peptide ^37,43Gap27 directed against exosomal Cx43 markedly alleviated the fluorescence intensity of Dio-rExo in U251s cells. These results suggest that exosomal Cx43 not only upregulates Cx43 expression in U251s cells, but also facilitates exosome uptake via Cx43.

Figure 3.

Role of exosomal Cx43 in exosome uptake by glioma cells. (A) Expression level of Cx43 in sExo and rExo. GAPDH was used as endogenous reference. (B) Expression of Cx43 in U251s cells after treatment with PBS, sExo and rExo for 48 h. GAPDH was used as endogenous reference. (C and D) The relative expression level of Cx43 was indicated as the ratio of Cx43/GAPDH in each group. Data represent the results of at least three independent experiments for each condition. **P<0.01, ***P<0.001. (E) Exosome uptake in U251s cells after treatment with Dio-sExo, Dio-rExo and Dio-rExo + ^37,43Gap27. U251s cells were incubated with Dio-stained sExo, rExo and Dio-rExo + ^37,43Gap27 for 30 min, then were counterstained with Hoechst 33342 (blue) for 5 min. Dio-stained exosome uptake (green) in cells was observed under fluorescence microscope. Scale bar, 100 µm. Cx43, connexin 43; U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells; Dio, dioctadecyloxacarbocyanine.

Exosomal Cx43 regulates TMZ resistance and colony formation ability of U251s cells

The aforementioned experiments demonstrated that exosomal Cx43 facilitated exosome uptake by U251s cells. Next, the role of exosomal Cx43 in development of TMZ resistance was examined. U251s cells were separately pretreated with PBS, sExo, rExo or rExo + ^37,43Gap27, followed by treatment with 0–800 µM TMZ. The results of the CCK-8 assay demonstrated that the IC₅₀ value of U251s cells to TMZ was ~220 µM in the PBS and sExo groups, while the IC₅₀ value of U251s cells to TMZ was increased to 580 µM in the rExo group (Fig. 4A and B). Additionally, ^37,43Gap27 significantly alleviated the rExo-induced increase in the IC₅₀ value of U251s cells to TMZ (P<0.001). Furthermore, the effect of exosomal Cx43 on the colony formation ability of U251s cells was examined. As shown in Fig. 4C and D, the colony number in the PBS and sExo groups was 25±6 and 38±4, respectively. By contrast, rExo significantly increased the colony number to 76±6 (P<0.001), whereas treatment with rExo + ^37,43Gap27 decreased the colony number to 51±7 (P<0.01). These results suggest that exosomal Cx43 enhances TMZ resistance and colony formation ability in glioma cells.

Figure 4.

Effect of exosomal Cx43 on TMZ resistance and colony formation ability of U251s cells. (A) U251s cell viability in each group was detected using Cell Counting Kit-8 assay at 72 h after treatment with TMZ, and the cell viability at each TMZ concentration was plotted for the dose-response curve. (B) IC₅₀ values of U251s cells to TMZ in the PBS, sExo, rExo and rExo + ^37,43Gap27 groups. Data represent the mean of at least three independent experiments for each condition. **P<0.01, ***P<0.001. (C) Colony formation assay was conducted in U251s cells treated with PBS, sExo, rExo and rExo + ^37,43Gap27. The representative images showed the colony morphology in each group. (D) Quantification of the number of colonies for statistical analysis. Data represent the results of three independent experiments for each group. **P<0.01, ***P<0.001. Cx43, connexin 43; TMZ, temozolomide; U251r, TMZ-resistant U251 glioma cells; U251s, TMZ-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells.

Exosomal Cx43 regulates the expression of Bcl-2, Bax and cleaved caspase-3 in U251s cells

The antineoplastic effect of TMZ is mediated by inducing intrinsic apoptosis and cell cycle arrest. Bcl-2 family proteins and caspases are important regulators of the intrinsic apoptosis pathway, which includes the pro-apoptotic (Bax), anti-apoptotic (Bcl-2) members and the cleavage of caspase-3. It has been reported that TMZ increases the Bax/Bcl-2 ratio in glioma cells, and dexamethasone induces TMZ resistance by maintaining the Bax/Bcl-2 ratio (36). Thus, effect of rExo on the expression of Bcl-2, Bax and cleaved caspase-3 in U251s cells was examined. Compared with the PBS and sExo groups, the expression of Bax and cleaved caspase-3 was significantly decreased and that of Bcl-2 was significantly increased in the rExo group. ^37,43Gap27 efficiently attenuated the rExo-induced changes in the expression of Bax, Bcl-2 and cleaved caspase-3 in U251s cells (Fig. 5A-C). These results indicated that exosomal Cx43 may enhance TMZ resistance through modulating the expression of pro-apoptotic and anti-apoptotic proteins and activation of caspase signaling.

Figure 5.

Effect of exosomal Cx43 on the expression of Bcl-2, Bax and cleaved caspase-3 in U251s cells. (A) Western blotting was used to detect the expression level of Bax, Bcl-2 and cleaved caspase-3 in U251s treated with PBS, sExo, rExo and rExo + ^37,43Gap27. GAPDH was used as endogenous control. (B, C and D) Relative expression levels of Bax, Bcl-2 and cleaved caspase-3 were indicated as the Bax/GAPDH, Bcl-2/GAPDH and cleaved caspase-3/GAPDH ratios in each group. Data represent the results of at least three independent experiments for each condition. *P<0.05, **P<0.01, ***P<0.001. Cx43, connexin 43; U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells.

Exosomal Cx43 enhances the migration ability of U251s cells

Glioma is a highly aggressive brain tumor. The strong migratory and invasive ability of glioma cells are closely associated with the poor prognosis of glioma. The present study further examined the effect of exosomal Cx43 on the migration ability of U251s cells. In the wound healing experiments, the migration of U251s cells at 0, 24 and 48 h in each group was photographed. As shown in Fig. 6A and B, rExo significantly increased the wound closure at 24 and 48 h compared to the PBS and sExo groups. ^37,43Gap27 efficiently inhibited rExo-induced wound closure in U251s cells. Consistently, the results of the Transwell assay also demonstrated that rExo enhanced the migration of U251s cells, whereas ^37,43Gap27 significantly alleviated rExo-induced cell migration (Fig. 6C and D). The results of the wound healing and Transwell assays suggest that Cx43 in rExo is involved in the regulation of glioma cell migration.

Figure 6.

Exosomal Cx43 enhances the migration ability of U251s cells. (A) Wound healing experiments were performed to evaluate the migration of U251s cells at 0, 24 and 48 h after treatment with PBS, sExo, rExo and rExo + ^37,43Gap27. Scale bar, 200 µm. (B) Wound closure rate was measured using ImageJ software for statistical analysis. Data represent the results of at least three independent experiments for each group. **P<0.01, ***P<0.001. (C) Transwell assay was used to examine the migration of U251s cells after treatment with PBS, sExo, rExo and rExo + ^37,43Gap27. Scale bar, 200 µm. (D) The migrated U251s cells were counted in at least 9 fields from three independent experiments for each treatment. **P<0.01. Cx43, connexin 43; U251r, temozolomide-resistant U251 glioma cells; U251s, temozolomide-sensitive U251 glioma cells; sExo, exosomes of U251s cells; rExo, exosomes of U251r cells.

Discussion

Glioma is one of the most common primary malignant brain tumors. Although TMZ is widely used for the treatment of primary and metastatic brain cancer, a considerable proportion of gliomas are refractory to TMZ or gradually develop resistance, which is the main reason for the failure of chemotherapy for glioma (37). It has been demonstrated that exosomes from glioma cells can promote tumor progression by transferring oncogenic and immunomodulatory proteins and nucleic acids between different cancer cell subsets or between cancer cells and surrounding stromal cells (38), which plays an important role in chemotherapy resistance. On the other hand, treatment with neuropilin-1-targeted peptide (RGE)-modified, superparamagnetic iron oxide nanoparticle (SPION)- and curcumin (Cur)-loaded exosomes, named RGE-Exo-SPION/Cur, has been reported to target glioma and prolong the survival time of tumor-bearing mice (39). Thus, it is necessary to further investigate the mechanisms underlying the role of exosomes in the resistance of glioma cells to TMZ.

It has been reported that Cxs are assembled into a hemi-channel in the exosomal membrane (24). The hemi-channel formed by Cxs on the plasma membrane can promote communication between the cytoplasm and the extracellular environment (40). Cx43 is the most common gap junction protein and is highly expressed in primary glioma cell lines (41). It has been reported that high expression of Cx43 is associated with the development of resistance of glioma cells to TMZ (31). In addition, a Cx43 C-terminus (CT) mimetic peptide-dubbed αCT1 (a selective inhibitor of Cx43 channels) combined with TMZ significantly blocked the growth of human LN229/GSC tumors in mice (41). Consistently, in the present study, higher expression of Cx43 was detected in U251r cells compared with that in U251s cells (Fig. 1). To explore the role of exosomal Cx43 in chemotherapy resistance, exosomes were initially isolated from U251s and U251r cells. Similar to parent cells, rExo expressed significantly higher Cx43 levels than sExo (Fig. 3A and C). Prior to incorporation, exosomes must dock and fuse with recipient cells. Thus, it is necessary to examine the role of exosomal Cx43 in exosome uptake by glioma cells. Although sExo and rExo uptake was observed in U251s cells, rExo with higher Cx43 expression was more readily incorporated into cells compared with sExo. In addition, the synthetic connexin 43 mimetic peptide ^37,43Gap27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment, and is widely used as a specific gap junction inhibitor directed against Cx43 (42,43). It has been reported that ^37,43Gap27 (100 nM-100 µM) attenuated hemi-channel activity in adult keratinocytes and fibroblasts sourced from juvenile foreskin. The expression level of Cx43 was also decreased when JF and AK cells were exposed to ^37,43Gap27 for 24 h (44). In the present study, ^37,43Gap27 directed against Cx43 markedly alleviated the uptake of rExo by U251s cells (Fig. 3E). These results suggest that exosomal Cx43 regulates the process of incorporation of exosomes into recipient cells. However, the mechanism underlying the role of exosomal Cx43 in exosome uptake remains to be further elucidated. It will be interesting to examine whether exosomal Cx43 cooperates with other membrane component molecules to facilitate docking or fusion with recipient cells. Next, the effect of exosomal Cx43 on the sensitivity of glioma cells to TMZ was examined. Treatment with rExo significantly increased the IC₅₀ value of U251s cells to TMZ and colony formation, whereas ^37,43Gap27 efficiently inhibited the effect of rExo on U251s cells (Fig. 4A-D). TMZ induces DNA damage and cell cycle arrest, which leads to an imbalance of Bcl-2 and Bax and activates the intrinsic apoptosis pathway in glioma cells (45). It was previously demonstrated that Cx43 reduces the sensitivity of human LN18 and LN229 glioma cells to TMZ by reducing the Bax/Bcl-2 ratio and the release of cytochrome c (29). Overexpression of Cx43 promotes the migration of U251 cells and inhibits apoptosis by upregulating Bcl-2 and downregulating the expression of Bax and caspase-3 (46). Thus, the effect of rExo on the expression of Bcl-2, Bax and cleaved caspase-3 in U251s cells was examined. As expected, rExo increased the expression of Bcl-2 and decrease Bax and cleaved caspase-3 in U251s cells, while ^37,43Gap27 alleviated the rExo-induced changes in the expression of Bax, Bcl-2 and cleaved caspase-3 in U251s cells (Fig. 5A-C). There are at least two plausible explanations for the role of exosomal Cx43 in the resistance of glioma cells to TMZ. First, the exosomal Cx43 may enhance TMZ resistance through modulating the expression of the pro-apoptotic and anti-apoptotic proteins and inhibiting the intrinsic apoptosis pathway (29,46). Second, high expression of Cx43 in rExo may contribute to the formation of gap junction channels between exosomes and recipient cells, which facilitates transferring various TMZ resistance-related factors from exosomes to U251s cells. Furthermore, the role of exosomal Cx43 in the migration of glioma cells was also examined. The results of the wound healing and Transwell assays demonstrated that rExo promoted the migration of U251s cells, and ^37,43Gap27 efficiently alleviated rExo-induced cell migration (Fig. 6). In previous studies, gap junctions have been demonstrated to serve as an important regulator of cell migration during tumor metastasis, although some results are controversial. For example, increased expression of Cx26 has been reported to enhance the invasion of lung squamous cell carcinoma (47). However, overexpression of Cx26 and Cx43 has also been found to slow down the migration of breast cancer cells (48,49). By contrast, the present study demonstrated that rExo with high Cx43 expression accelerated the migration of U251s cells. One possible explanation is that Cx43-assembled gap junction channels facilitate the delivery of effector molecules promoting migration from exosomes to U251s cells. Another explanation is that the response of glioma cells may differ from that of breast cancer cells.

In conclusion, the results of the present study may provide new insight into the role of exosomal Cx43 in the resistance of glioma cells to TMZ and cell migration. Cx43 was found to be highly expressed in TMZ-resistant U251r cells and rExo. Furthermore, treatment with rExo enhanced the resistance of U251s cells to TMZ, their colony formation and migration abilities, and changeed the expression pattern of Bax and Bcl-2. ^37,43Gap27 directed against exosomal Cx43 significantly attenuated rExo-induced TMZ resistance, colony formation, cell migration and alterations in the expression of Bax and Bcl-2. These results indicate the important role of exosomal Cx43 in TMZ resistance and migration of glioma cells, and suggest a promising new strategy for preventing chemotherapy resistance and reducing the aggressiveness of glioblastoma by targeting exosomal Cx43 in the future.

Glossary

Abbreviations

Cx43

connexin 43

TMZ

temozolomide

U251r

TMZ-resistant U251 cells

U251s

TMZ-sensitive U251 cells

Exo

exosome

Dio

dioctadecyloxacarbocyanine

Funding Statement

The present study was supported by the National Natural Science Foundation of China (grant nos. 81660014 and 81660159), the Key Program of the Natural Science Foundation of Jiangxi Province (grant no. 20202ACB206001), the Key Research and Development Program of Jiangxi Province (grant nos. 20192BBG70012 and 20192BBG70049), and the Research Fund for Key Laboratory of Drug Targets and Drug Screening of Jiangxi Province (grant no. 20171BCD40007).

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81660014 and 81660159), the Key Program of the Natural Science Foundation of Jiangxi Province (grant no. 20202ACB206001), the Key Research and Development Program of Jiangxi Province (grant nos. 20192BBG70012 and 20192BBG70049), and the Research Fund for Key Laboratory of Drug Targets and Drug Screening of Jiangxi Province (grant no. 20171BCD40007).

Availability of data and materials

The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

LPJ and XJH designed the current project. ZJY, LLZ, QCB, LJG, RJT, XML and LHL performed the experiments. LPJ, XJH, TH, MJW, ZJY and LLZ analyzed the data. ZJY, XJH and LLZ drafted the manuscript. LPJ, XJH and TH supervised the study. LPJ and XJH have seen and can confirm the authenticity of the raw data. All the authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.